ew strategies to detect cancers in carriers of mutations in RB1: blood tests based on tumor-educated platelets, or extracellular vesicles.
Recruiting
- Conditions
- Retinoblastoma
- Registration Number
- NL-OMON28055
- Lead Sponsor
- one
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 396
Inclusion Criteria
criteria:
- Adult:
o Group 1: germline mutation RB1.
o Group 2 (control): no germline mutation RB1.
- Pediatric:
o Group 1: somatic or germline mutation RB1
o Group 2 (control): no mutation RB1.
Exclusion Criteria
- Adult:
o Group 1: concomitant heritable (inherited) disorder other than caused by monoalleic mutation of RB1.
o Group 2 (control): cancer or already known cancer predisposition syndrome.
- Pediatric:
o Group 1: concomitant heritable (inherited) disorder other than caused by monoalleic mutation of RB1.
o Group 2: cancer or already known cancer predisposition syndrome.
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1. Determine the non-cancerous baseline in adult RB1-mutation carriers (Rb-survivors).<br>2. Contribute to the biobanking of blood and cancerous tissues from RB1-mutation carriers with SPMs.
- Secondary Outcome Measures
Name Time Method